In Vitro Fertilizasyon (IVF) Yapılan Polikistik Over Sendromlu Kadınların Gebelik Komplikasyonlarının Değerlendirilmesi

Abstract

Objectives: The aim of the study is to compare the pregnancy complications including particularly gestational diabetes mellitus (GDM) and preeclampsia of women having polycystic ovarian syndrome (PCOS), with normal pregnancy complications. Materials and Methods: To investigate the impact of PCOS on pregnancy complications, we retrospectively compared the pregnant patients (diagnosed with PCOS) with normal pregnant patients who became pregnant using the intra cytoplasmic sperm injection method, having same age and body mass index, at İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Obstetrics and Gynecology, In Vitro Fertilization Unit between 2002 and 2011. Results: When the patients diagnosed with PCOS and control group were compared in terms of the pregnancy complications, early pregnancy loss and GDM were found to be statistically significant. (respectively p=0.005, p=0.013). The interaction between early pregnancy loss and gestational diabetes with age, body mass index, gestational weight gain, fasting glucose, fasting insulin and Homeostasis Model Assessment (HOMA-IR) values were investigated with the Spearman correlation analysis. While the gestational weight gain was negatively correlated with early pregnancy loss; age, fasting glucose, fasting insulin and HOMA-IR were positively correlated with gestational diabetes (p=0.001 for early pregnancy loss; p=0.005, p=0.001, p=0.005, p=0.001 respectively for GDM). Conclusion: Early pregnancy loss and GDM are seen more often in polycystic ovary syndrome. Early pregnancy loss of pregnant women with PCOS was found to be high independent of the blood sugar regulation parameters of the patients.

Keywords

• Polycstic Ovarian Syndrome
• GDM
• Preeclampsia
• Early Pregnancy Loss
• Pregnancy Complications

References

1. 1. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRMSponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28-38.
2. 2. Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.
3. 3. Zeng X, Xie YJ, Liu YT, et al. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-221.
4. 4. González F, Considine RV, Abdelhadi OA, et al. Inflammation Triggered by Saturated Fat Ingestion Is Linked to Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2020;105:2152-2167.
5. 5. Wild RA. Long-term health consequences of PCOS. Hum Reprod Update. 2002;8:231-241.
6. 6. Bannigida DM, Nayak BS, Vijayaraghavan R. Insulin resistance and oxidative marker in women with PCOS. Arch Physiol Biochem. 2020;126:183-186.
7. 7. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676-682.
8. 8. Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med. 2008;26:72-84.

9. 9. Hatch R, Rosenfield RL, Kim MH, et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815-830 . 10. Balen AH, Laven JS, Tan SL, et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505-514.
10. 11. Heijnen EM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:13-21.
11. 12. Joham AE, Boyle JA, Ranasinha S, et al. Contraception use and pregnancy outcomes in women with polycystic ovary syndrome: data from the Australian Longitudinal Study on Women’s Health. Hum Reprod. 2014;29:802-808.
12. 13. Liu S, Mo M, Xiao S, et al. Pregnancy Outcomes of Women With Polycystic Ovary Syndrome for the First In Vitro Fertilization Treatment: A Retrospective Cohort Study With 7678 Patients. Front Endocrinol (Lausanne). 2020;11:575337.
13. 14. Hu M, Zhang Y, Guo X, et al. Hyperandrogenism and insulin resistance induce gravid uterine defects in association with mitochondrial dysfunction and aberrant reactive oxygen species production. Am J Physiol Endocrinol Metab. 2019;316:794-809.
14. 15. Glueck CJ, Wang P, Fontaine RN, et al. Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism. 1999;48:1589-1595.
15. 16. Okon MA, Laird SM, Tuckerman EM, et al. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril. 1998;69:682-690.
16. 17. Cermik D, Karaca M, Taylor HS. HOXA10 expression is repressed by progesterone in the myometrium: Differential tissue-specific regulation of HOX gene expression in the reproductive tract. J Clin Endocrinol Metab. 2001;86:3387-3392.
17. 18. Poolsup N, Suksomboon N, Amin M. Effect of treatment of gestational diabetes mellitus: a systematic review and meta-analysis. PLoS One. 2014;9:e92485.
18. 19. Sawada M, Masuyama H, Hayata K, et al. Pregnancy complications and glucose intolerance in women with polycystic ovary syndrome. Endocr J. 2015;62:1017-1023.
19. 20. Mills G, Badeghiesh A, Suarthana E , et al. Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies. Hum Reprod. 2020;35:1666-1674.
20. 21. Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol. 2011;204:558.
21. 22. Qin JZ, Pang LH, Li MJ, et al. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2013;11:56.
22. 23. Roos N, Kieler H, Sahlin L, et al. Risk of adverse pregnancy outcomes inwomen with polycystic ovary syndrome: population based cohort study. BMJ. 2011;343:d6309.
23. 24. Siassakos D, Wardle P. Polycystic ovary syndrome and pregnancy outcome:red herring or red flag? BJOG. 2007;114:922-932.
24. 25. Bahri Khomami M, Earnest A, Loxton D, et al. Predictors of hypertensive disorders in pregnancy in women with and without polycystic ovary syndrome: The Australian Longitudinal Study of Women’s Health. Clin Endocrinol (Oxf). 2021;95:323-331.
25. 26. Manoharan V, Wong VW. Impact of comorbid polycystic ovarian syndrome and gestational diabetes mellitus on pregnancy outcomes: a retrospective cohort study. BMC Pregnancy Childbirth. 2020;20:484.
26. 27. Cho LW, Randeva HS, Atkin SL. Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag. 2007;3:55-63.
27. 28. Naver KV, Grinsted J, Larsen SO, et al. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia. BJOG. 2014;121:575-581.
28. 29. Thomann R, Rossinelli N, Keller U, et al. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:199-206.
29. 30. Mikola M, Hiilesmaa V, Halttunen M, et al. Obstetric outcome in womenwith polycystic ovarian syndrome. Hum Reprod. 2001;16:226-229.
30. 31. Haakova L, Cibula D, Rezabek K, et al. Pregnancy outcome in womenwith PCOS and in controls matched by age and weight. Hum Reprod. 2003;18:1438-1441.
31. 32. Yu CK, Teoh TG, Robinson S. Obesity in pregnancy.BJOG 2006;113:1117-1125.
32. 33. Mills G, Badeghiesh A, Suarthana E, et al. Associations between polycystic ovary syndrome and adverse obstetric and neonatal outcomes: a population study of 9.1 million births. Hum Reprod. 2020;35:1914-1921.